title: Dissolution enhancement of glibenclamide by solid dispersion: solvent evaporation versus a supercritical fluid-based solvent -antisolvent technique.
abstract: Glibenclamide (GLIB) is a poorly soluble drug with formulation-dependent bioavailability. Therefore, we attempted in this study to improve GLIB dissolution rate by preparing drug solid dispersions by solvent evaporation (SE) and supercritical fluid solvent-antisolvent techniques (SCF-SAS). A D-optimal mixture design was used to investigate the effects of different ratios of HPMCE5 (50-100%), PEG6000 (0-40%), and Poloxamer407 (0-20%) on drug dissolution from different solid dispersion (SD) formulations prepared by SE. The ratios of carriers used in SCF-SAS method were HPMCE5 (fixed at 60%), PEG6000 (20-40%), and Poloxamer407 (0-20%). A constant drug: carrier weight ratio of 1:10 was used in all experiments. The SDs obtained were physically characterized and subjected to the dissolution study. The major GLIB bands in FTIR spectra were indicative of drug integrity. The reduced intensity and the fewer number of peaks observed in X-ray diffractograms (XRD) of GLIB formulations was the indicative of at least partial transformation of crystalline to amorphous GLIB. This change and/or dilution of drug in much higher amounts of carriers present caused disappearance of distinctive endothermic peaks in differential scanning calorimetry thermograms of GLIB formulations. The model generated according to the results of the D-optimal mixture design indicated that GLIB formulations comprising HPMC (50%-60%), PEG (34-40%), and poloxamer (6-10%) had enhanced dissolution performances. As compared to SE method, the SCF-SAS technique produced formulations of higher dissolution performances, likely due to the effects of solution and the supercritical CO2 (SC-CO2) on enhanced plasticization of polymers and thus increased diffusion of the drug into the polymer matrix.
authors: Department of Pharmaceutics and Novel Drug Delivery Systems Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
authors: M
authors: M
authors: Tabbakhian
authors: Department of Medicinal Chemistry and Novel Drug Delivery Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
authors: F
authors: F
authors: Hasanzadeh
authors: Department of Pharmaceutics and Novel Drug Delivery Systems Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
authors: N
authors: N
authors: Tavakoli
authors: Students Research Committee, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
authors: Z
authors: Z
authors: Jamshidian
keywords: Dissolution enhancement; Glibenclamide; Solid dispersion; Solvent evaporation; Supercritical fluid
references: Eur J Pharm Biopharm. 2012 Jan;80(1):203-8
references: 21907802
references: J Pharm Biomed Anal. 2005 Feb 7;37(1):65-71
references: 15664744
references: Int J Pharm. 2008 Dec 8;364(2):176-87
references: 18597957
references: AAPS PharmSciTech. 2007 Apr 13;8(2):Article 29
references: 17622107
references: Eur J Pharm Sci. 2006 Sep;29(1):45-52
references: 16815694
references: AAPS PharmSciTech. 2007 Dec 14;8(4):E108
references: 18181529
references: Int J Pharm. 2001 Jul 3;222(1):139-51
references: 11404040
references: Int J Pharm. 2007 Mar 6;332(1-2):132-9
references: 17055198
references: Eur J Pharm Sci. 2001 May;13(2):123-33
references: 11297896
references: Eur J Pharm Sci. 2005 Oct;26(2):184-93
references: 16081259
references: Int J Pharm. 2005 Sep 14;301(1-2):199-208
references: 16024189
references: Eur J Pharm Sci. 2000 Mar;10(1):43-52
references: 10699382
references: J Pharm Sci. 2008 Jun;97(6):2110-20
references: 17847067
references: Arch Pharm Res. 2008 Nov;31(11):1497-507
references: 19023548
references: Pharm Res. 2000 Apr;17(4):439-44
references: 10870988
references: Eur J Pharm Sci. 2006 Jan;27(1):62-71
references: 16213127
references: Adv Drug Deliv Rev. 2008 Feb 14;60(3):399-410
references: 17964684
references: Drug Discov Today. 2007 Dec;12(23-24):1068-75
references: 18061887
references: AAPS PharmSciTech. 2009;10(2):660-9
references: 19459053
references: Int J Pharm. 2007 Mar 21;333(1-2):152-61
references: 17223289
references: J Control Release. 1999 Aug 27;61(1-2):43-50
references: 10469901
references: Eur J Pharm Biopharm. 2000 Jul;50(1):47-60
references: 10840192
references: Int J Pharm. 2012 Feb 28;423(2):471-9
references: 22183131
references: Eur J Pharm Biopharm. 2008 Aug;69(3):1046-56
references: 18374555
references: Int J Pharm. 2005 Mar 23;292(1-2):1-16
references: 15725549
references: Adv Drug Deliv Rev. 2008 Feb 14;60(3):373-87
references: 18069079
references: Pharm Res. 2006 Dec;23 (12 ):2709-28
references: 17096184
references: Dis Mon. 2005 Jun;51(6):362-73
references: 16242521